PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Psilocybin Feasible for Treatment-Resistant Depression in NHS Setting

psilocybinCOMP360serotonergic psychedelicstreatment-resistant depressionmajor depressive disorderfeasibility RCTpsychopharmacologyNHSMADRSpsychedelic-assisted therapy Psychiatry / Psychopharmacology

Background Information

Psilocybin shows promise for treatment-resistant major depression.

This study explores psilocybin as a potential treatment for patients with treatment-resistant major depressive disorder, which is a difficult-to-treat condition. The study found a significant improvement in depression scores with psilocybin compared to placebo, with a difference of -10.41 on the MADRS at week 3. These results suggest psilocybin could be beneficial for some patients with treatment-resistant depression, but a confirmatory trial is needed. The study was limited by its small size and feasibility-focused design. Psilocybin shows promise for treatment-resistant depression, warranting further investigation.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, Campbell-Coker K, Hambleton S, Seath P, Hignett R, Fennema D, Hampsey E, Tsapekos D, Thomas RJ, Cattell J, Jafari H, Day C, Borissova A, Lloyd M, Boardman-Pretty T, Seynaeve M, Askari F, Creed M, Baxter L, Rifkin-Zybutz R, Butler M, Jelen LA, Carter B, Young AH

Citation: Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature medicine. 2026;32(9):3430-3437. doi:10.1038/s41591-026-04541-0

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.